Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses

摘要

The present invention relates to the identification of new peptides and peptidomimetics which bind the CXCR4 receptor, capable of forming complexes with receptors for chemokines, in particular with CXCR4. The invention also relates to the use of these peptides for the treatment, prevention and diagnosis of diseases which involve chemokine receptors (i.e. neoplasias, metastases, HIV-1 virus infections), and also the mobilization of stem cells of hemopoietic precursors in the case of autologous transplants. Finally, the invention comprises pharmaceutical compositions and diagnostic kits comprising said peptides.

主权项

1. Cyclic monomeric peptides containing up to eight amino acids characterised in that they exert an agonist or antagonist action on the CXCR4 receptor and that they have the following general formula
(I): wherein: the N- terminal group Nt of the peptide is selected between free amine and acetyl (Ac); the C terminal group Ct of the peptide is selected between free carboxylate, and primary amide (Nam); the N terminal sequence (Ns) optionally present has a formula selected between B-x-; and B-x-x; the C terminal sequence (Cs) optionally present is -x-B; wherein B represents an encoded basic amino acid residue selected from lysine (K) and arginine (R) and wherein x represents an encoded amino acid residue selected from glycine (G), alanine (A) and proline (P); wherein said sequences (Ns) and (Cs) may be present with mutual exclusion or both be absent; both amino acid residues Nc and Cc, are cysteine (C) and are both present; the bond tc that involves the amino acid residues Nc and Cc in the ring formation is—a disulphide bridge between cysteine side chains (css); the central sequence X1-X2-X3 is selected from Ar1-Ar2-R and R-Ar2-Ar1, wherein R is arginine, and Ar1-Ar2 are encoded aromatic residues selected from phenylalanine (F), tryptophan (W), tyrosine (Y) and histidine (H); or pharmacologically acceptable salts thereof.